Company intelligence / Profile preview

Obsidian Sciences

Cambridge, Massachusetts, USAmindat.org ↗

Ownership: Private
Employees: ~49
Development stage: Other

Overview

OBX-115, the company's lead engineered TIL therapy, is in clinical trials for advanced melanoma and NSCLC. Initial results show it may be as efficacious as currently approved products but with a better safety profile, eliminating the need for co-treatment with IL-2[4].

Therapeutic areas: Oncology
Modalities: Cell therapyGene therapyEngineered TIL (Tumor Infiltrating Lymphocyte) therapy
Industry: Biotech

Partnerships

Celgene (mentioned as a partner)[6]

Beyond the preview

Go deeper on Obsidian Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Obsidian Sciences.

Explore the full profile